Psilocybin therapy is employed for individuals who are resistant to current therapeutic methods. This approach has shown success in alleviating depression, anxiety, or the feeling of fear and disappointment related to illness particularly in individuals with cancer. It is used as a treatment option for individuals who have been resistant to the current treatment approaches for depression. This method has high potential in reducing symptoms of depression and anxiety and promoting long-lasting recovery. Furthermore, psilocybin therapy has shown promising results for patients with post-traumatic stress disorder (PTSD). It has demonstrated notable positive effects in treating this condition.

Due to the expansive therapeutic index of psilocybin (1:1000) and a generally unattainable lethal dose, psilocybin boasts a favorable safety profile. In comparison to other psychedelics like MDMA and DMT, psilocybin exhibits a lower incidence of seizures, hospital admissions, and other severe adverse effects. Additionally, it lacks addictive or reinforcing properties. Several dose-escalating studies, involving supratherapeutic doses such as 50–60 mg or 5–6 grams, have yielded positive results with minimal safety concerns.